Original Article
Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease
N Engl J Med 2005; 353:46-57July 7, 2005
- Abstract
Background
Lp(a) lipoprotein binds proinflammatory oxidized phospholipids. We investigated whether levels of oxidized low-density lipoprotein (LDL) measured with use of monoclonal antibody E06 reflect the presence and extent of obstructive coronary artery disease, defined as a stenosis of more than 50 percent of the luminal diameter.
Methods
Levels of oxidized LDL and Lp(a) lipoprotein were measured in a total of 504 patients immediately before coronary angiography. Levels of oxidized LDL are reported as the oxidized phospholipid content per particle of apolipoprotein B-100 (oxidized phospholipid:apo B-100 ratio).
Results
Measurements of the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels were skewed toward lower values, and the values for the oxidized phospholipid:apo B-100 ratio correlated strongly with those for Lp(a) lipoprotein (r=0.83, P<0.001). In the entire cohort, the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels showed a strong and graded association with the presence and extent of coronary artery disease (i.e., the number of vessels with a stenosis of more than 50 percent of the luminal diameter) (P<0.001). Among patients 60 years of age or younger, those in the highest quartiles for the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels had odds ratios for coronary artery disease of 3.12 (P<0.001) and 3.64 (P<0.001), respectively, as compared with patients in the lowest quartile. The combined effect of hypercholesterolemia and being in the highest quartiles of the oxidized phospholipid:apo B-100 ratio (odds ratio, 16.8; P<0.001) and Lp(a) lipoprotein levels (odds ratio, 14.2; P<0.001) significantly increased the probability of coronary artery disease among patients 60 years of age or younger. In the entire study group, the association of the oxidized phospholipid:apo B-100 ratio with obstructive coronary artery disease was independent of all clinical and lipid measures except one, Lp(a) lipoprotein. However, among patients 60 years of age or younger, the oxidized phospholipid:apo B-100 ratio remained an independent predictor of coronary artery disease.
Conclusions
Circulating levels of oxidized LDL are strongly associated with angiographically documented coronary artery disease, particularly in patients 60 years of age or younger. These data suggest that the atherogenicity of Lp(a) lipoprotein may be mediated in part by associated proinflammatory oxidized phospholipids.
Media in This Article
Figure 1
Frequency Distribution of the Oxidized Phospholipid:Apo B-100 Ratio (Panel A) and Lp(a) Lipoprotein Levels (Panel B).Figure 2
Association of the Oxidized Phospholipid:Apo B-100 Ratio and Lp(a) Lipoprotein Levels to the Extent of Coronary Artery Disease (CAD) in 239 Patients 60 Years of Age or Younger and 265 Patients Older Than 60 Years.Article Activity
- Article
Human coronary atherosclerosis is a chronic inflammatory disease that is superimposed on a background of lipid abnormalities. Proinflammatory oxidized low-density lipoprotein (LDL) may be a unifying link between lipid accumulation and inflammation in the vessel wall. In humans, oxidized LDL in plasma and within atherosclerotic lesions is strongly associated with coronary artery disease, acute coronary syndromes, and vulnerable plaques.1-7
Lp(a) lipoprotein is a lipoprotein of unknown physiologic function that is composed of apolipoprotein B-100 (apo B-100) to which apolipoprotein(a) is covalently bound. Increased plasma levels of Lp(a) lipoprotein are independent predictors of the presence of angiographically documented and clinical coronary artery disease, particularly in patients with hypercholesterolemia.8 However, the underlying mechanisms by which Lp(a) lipoprotein contributes to the pathogenesis of atherosclerosis are not well understood. We recently showed that proinflammatory oxidized phospholipids are strongly associated with Lp(a) lipoprotein in human plasma.5-7,9 Therefore, we hypothesized that the presence of oxidized phospholipids on apo B-100–containing lipoproteins may explain some of the atherogenic properties of Lp(a) lipoprotein, and we designed this study to evaluate the relationship between circulating oxidized LDL, Lp(a) lipoprotein, and angiographically documented coronary artery disease.
Methods
Study Design
We designed the current study on the basis of a previous study in which we had enrolled a total of 504 consecutive patients (97.2 percent of whom were white), 18 to 75 years of age, who were undergoing clinically indicated coronary angiography at the Mayo Clinic between June 1998 and December 1998.10 Race was self-reported. The exclusion criteria, which have been described previously, included prior coronary revascularization and the presence of diabetes mellitus.10 Arterial plasma samples were obtained from the femoral sheath before angiography and were placed in tubes containing EDTA and frozen at –70°C until the analyses were performed. Hypercholesterolemia was defined as a total cholesterol level of at least 250 mg per deciliter (6.5 mmol per liter), an LDL level of at least 150 mg per deciliter (3.9 mmol per liter), or ongoing treatment with lipid-lowering agents. The study was approved by the Mayo Clinic institutional review board, and all patients gave written informed consent.
Angiographic Analysis
The maximal stenosis in each of 27 coronary-artery segments was assessed by a cardiologist, who was unaware of risk factors, with the use of handheld calipers or in visual analysis according to the segmental classification system of the Coronary Artery Surgery Study. The extent of angiographically documented coronary artery disease was quantified as follows: normal coronary arteries (smooth, with either no stenosis or a stenosis of <10 percent of the luminal diameter), mild disease (a stenosis of 10 to 50 percent of the luminal diameter in one or more coronary arteries or their major branches), or one-vessel, two-vessel, or three-vessel disease, defined as a stenosis of more than 50 percent of the luminal diameter in one, two, or three coronary arteries or their major branches.10
Laboratory Analyses
Analyses of apo B-100, Lp(a) lipoprotein, total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides were performed with the use of commercially available kits. LDL cholesterol was estimated with the use of the Friedewald formula. High-sensitivity C-reactive protein (CRP) (lower limit of detection, 0.15 mg per liter) was measured as described elsewhere.11
Our assay of oxidized LDL determines the content of oxidized phospholipids per particle of apo B-100 (oxidized phospholipid:apo B-100 ratio) and is performed with the use of the murine monoclonal antibody E06, which specifically binds to the phosphorylcholine moiety of oxidized but not native phospholipids.6,7 We have previously used the term OxLDL-E06 to describe the name of this assay. In brief, a dilution of plasma at 1:50 in phosphate-buffered saline was added to microtiter wells coated with monoclonal antibody MB47, which specifically binds apo B-100 particles. Under these conditions, a saturating amount of apo B-100 was added to each well, and consequently, equal numbers of apo B-100 particles were captured in each well for all assays. The oxidized phospholipid:apo B-100 ratio was measured by chemiluminescent enzyme-linked immunosorbent assay with the use of biotinylated E06, as described elsewhere.6,7
Statistical Analysis
Discrete data are presented as frequencies and percentages, and continuous variables as means and standard deviations or as medians and interquartile ranges if the distributions were skewed. Spearman's correlation coefficient was used to measure the linear associations between the rank values of the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels as well as lipid levels and other clinical risk factors. The association of the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels with the extent of coronary artery disease was tested by one-way analysis of variance of the log-transformed values followed by a one-degree-of-freedom test for trend. The percentages of patients with obstructive coronary artery disease and the odds ratios were calculated for quartiles of the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels for all patients, according to age (≤60 years or >60 years), and according to the presence or absence of hypercholesterolemia.
Logistic-regression models were used to estimate the associations between patients' characteristics and lipid measurements and obstructive coronary artery disease. Multiple logistic-regression analysis was used to estimate the partial associations between the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels and obstructive coronary artery disease, with adjustment for age, sex, smoking status, the presence or absence of hypertension, and levels of LDL cholesterol, HDL cholesterol, triglycerides, and CRP. The base-2 logarithms (log2) of the oxidized phospholipid:apo B-100 ratio and the levels of Lp(a) lipoprotein, triglycerides, and CRP were used in all the logistic-regression models to account for skewness in the distributions. Thus, odds ratios for these variables reflect the change in odds for an increase of 1 log2 (the equivalent of a doubling of the value) in the measure.
Results
The baseline clinical characteristics of the patients, indications for coronary angiography, lipid measurements, and CRP levels are shown in Table 1Table 1
Baseline Characteristics and Lipid Levels in the Study Group.. The distributions of both the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels were skewed toward lower values, with 85 percent of the patients having levels lower than 0.4 and 45 mg per deciliter, respectively (Figure 1Figure 1Frequency Distribution of the Oxidized Phospholipid:Apo B-100 Ratio (Panel A) and Lp(a) Lipoprotein Levels (Panel B).). In the entire population, a strong correlation (r=0.83, P<0.001) was noted between the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels.Association with the Extent of Angiographically Documented Disease
In the entire study group, the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels were strongly associated with a graded increase in the extent of coronary artery disease (P<0.001 for both analyses) (data not shown). These relationships were markedly stronger for patients 60 years of age or younger than for patients older than 60 years (Figure 2Figure 2
Association of the Oxidized Phospholipid:Apo B-100 Ratio and Lp(a) Lipoprotein Levels to the Extent of Coronary Artery Disease (CAD) in 239 Patients 60 Years of Age or Younger and 265 Patients Older Than 60 Years.).Association with Obstructive Coronary Artery Disease
The proportion of patients with obstructive coronary artery disease increased consistently with increases in the oxidized phospholipid:apo B-100 ratio and in Lp(a) lipoprotein levels (Table 2Table 2
Odds Ratios for Obstructive Coronary Artery Disease (CAD) According to Quartiles for the Ratio of Oxidized Phospholipids to Apolipoprotein B-100 and Levels of Lp(a) Lipoprotein.). This association was particularly evident among patients 60 years of age or younger, among whom the highest quartiles of the oxidized phospholipid:apo B-100 ratio (odds ratio, 3.12; P<0.001) and Lp(a) lipoprotein levels (odds ratio, 3.64, P<0.001) were associated with a significantly higher risk, as compared with the lowest quartiles. This association was not present among patients older than 60 years.The combined effects of hypercholesterolemia plus either the oxidized phospholipid:apo B-100 ratio or Lp(a) lipoprotein levels greatly increased the probability of obstructive coronary artery disease. When compared with patients in the lowest quartile who did not have hypercholesterolemia, patients in the highest quartile of the oxidized phospholipid:apo B-100 ratio or Lp(a) lipoprotein levels who had hypercholesterolemia were significantly more likely to have obstructive coronary artery disease (Table 3Table 3
Odds Ratios for Obstructive Coronary Artery Disease (CAD) According to Quartiles of the Ratio of Oxidized Phospholipids to Apolipoprotein B-100 and Levels of Lp(a) Lipoprotein in Patients without and with Hypercholesterolemia (HC).). These relationships were markedly accentuated among patients 60 years of age or younger (for the oxidized phospholipid:apo B-100 ratio, odds ratio, 16.8 [P<0.001]; for Lp(a) lipoprotein levels, odds ratio, 14.2 [P<0.001]), as compared with those older than 60 years (for the oxidized phospholipid:apo B-100 ratio, odds ratio, 4.95 [P=0.003]; for Lp(a) lipoprotein levels, odds ratio, 4.92 [P=0.007]).The relationship of the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels to coronary artery disease remained fundamentally similar after the exclusion from analysis of 41 patients with acute myocardial infarction within six weeks before enrollment. Also, there was a stronger association between the oxidized phospholipid:apo B-100 ratio and Lp(a) lipoprotein levels and coronary artery disease in patients with hypercholesterolemia who were taking statins than among such patients who were not taking statins, but differences in the odds ratios were not statistically significant (data not shown).
Predictors of Obstructive Coronary Artery Disease
Without adjustment for other risk factors, the oxidized phospholipid:apo B-100 ratio was predictive of obstructive coronary artery disease (odds ratio per doubling, 1.19; 95 percent confidence interval, 1.05 to 1.34; P=0.005) as was the Lp(a) lipoprotein level (odds ratio per doubling, 1.22; 95 percent confidence interval, 1.07 to 1.40; P=0.003). Similarly, male sex (odds ratio, 4.33; 95 percent confidence interval, 2.95 to 6.35; P<0.001), age (odds ratio per decade, 1.48; 95 percent confidence interval, 1.25 to 1.75; P<0.001), current smoking (odds ratio, 1.65; 95 percent confidence interval, 1.16 to 2.35; P=0.006), hypertension (odds ratio, 1.81; 95 percent confidence interval, 1.27 to 2.58; P=0.001), LDL cholesterol (odds ratio per increase of 25 mg per deciliter [0.65 mmol per liter], odds ratio, 1.28; 95 percent confidence interval, 1.12 to 1.45; P=0.003), and triglyceride levels (odds ratio per doubling, 1.27; 95 percent confidence interval, 1.00 to 1.61; P=0.05) were also predictive, whereas HDL cholesterol (odds ratio per increase of 10 mg per deciliter [2.3 mmol per liter], 0.64; 95 percent confidence interval, 0.56 to 0.74; P<0.001) was a negative predictor. CRP (odds ratio per doubling, 1.08; 95 percent confidence interval, 0.98 to 1.19; P=0.12) was not a predictor of obstructive coronary artery disease.
Among patients 60 years of age or younger, the odds ratios per doubling for the oxidized phospholipid:apo B-100 ratio (1.43; 95 percent confidence interval, 1.20 to 1.71; P<0.001) and Lp(a) lipoprotein level (1.41; 95 percent confidence interval, 1.16 to 1.73; P<0.001) were significant, whereas among those older than 60 years they were no longer significant (for the oxidized phospholipid:apo B-100 ratio: odds ratio per doubling, 1.05; 95 percent confidence interval, 0.89 to 1.25; P=0.58; and for Lp[a] lipoprotein levels: odds ratio per doubling, 1.09; 95 percent confidence interval, 0.90 to 1.32; P=0.37).
Multivariable analysis with the use of logistic-regression models to derive adjusted odds ratios for coronary artery disease showed that an increase in the oxidized phospholipid:apo B-100 ratio (odds ratio per doubling, 1.21; 95 percent confidence interval, 1.05 to 1.39; P=0.007) was an independent predictor of obstructive coronary artery disease, as were male sex (odds ratio, 4.27; 95 percent confidence interval, 2.59 to 7.03; P<0.001), age (odds ratio per decade, 1.72; 95 percent confidence interval, 1.41 to 2.10; P<0.001), an increase in LDL cholesterol (odds ratio per 25 mg per deciliter, 1.28; 95 percent confidence interval, 1.11 to 1.48; P<0.001), and hypertension (odds ratio, 1.67; 95 percent confidence interval, 1.10 to 2.52; P=0.016), whereas an increase in HDL cholesterol levels (odds ratio per 10 mg per deciliter, 0.75; 95 percent confidence interval, 0.63 to 0.90; P=0.002) was a negative predictor. An increase in CRP (odds ratio per doubling, 1.09; 95 percent confidence interval, 0.97 to 1.22; P=0.16) was not a predictor of obstructive coronary artery disease. When Lp(a) lipoprotein was added to the model and the oxidized phospholipid:apo B-100 ratio was removed, Lp(a) lipoprotein was also an independent predictor (odds ratio per doubling, 1.20; 95 percent confidence interval, 1.02 to 1.40; P=0.02). As in the unadjusted data, the odds ratios per doubling for the oxidized phospholipid:apo B-100 ratio (1.49; 95 percent confidence interval, 1.20 to 1.84; P<0.001) and for Lp(a) lipoprotein (1.42; 95 percent confidence interval, 1.12 to 1.81; P=0.004) among patients 60 years of age or younger were significantly accentuated, whereas among those older than 60 years they were no longer significant (for the oxidized phospholipid:apo B-100 ratio: odds ratio per doubling, 1.00; 95 percent confidence interval, 0.82 to 1.22; P=0.96; for Lp(a) lipoprotein: odds ratio per doubling, 1.05; 95 percent confidence interval, 0.84 to 1.31; P=0.69).
Interestingly, in the entire study group, when Lp(a) lipoprotein was forced into the model with the oxidized phospholipid:apo B-100 ratio, there was a trend toward significance of the oxidized phospholipid:apo B-100 ratio (odds ratio per doubling, 1.21; 95 percent confidence interval, 0.95 to 1.54; P=0.12), whereas Lp(a) lipoprotein levels no longer remained an independent predictor of coronary artery disease (odds ratio per doubling, 1.00; 95 percent confidence interval, 0.76 to 1.32; P=0.99). However, when patients were analyzed according to age, the oxidized phospholipid:apo B-100 ratio, but not Lp(a) lipoprotein levels, was an independent predictor of obstructive coronary artery disease among those 60 years of age or younger, but not among those older than 60 years (Figure 3Figure 3
Odds Ratios for Obstructive Coronary Artery Disease (CAD) Associated with Selected Risk Factors among Patients 60 Years of Age or Younger and Those Older Than 60 Years, from the Multivariable Analysis.). CRP was also a predictor of obstructive coronary artery disease among patients 60 years of age or younger, but not among those older than 60 years. When the 41 patients with acute myocardial infarction, who also had the highest levels of CRP, were removed from the analysis, CRP was no longer a predictor of obstructive coronary artery disease (odds ratio per doubling, 1.06; 95 percent confidence interval, 0.85 to 1.33; P=0.58), but the oxidized phospholipid:apo B-100 ratio (odds ratio per doubling, 1.55; 95 percent confidence interval, 1.05 to 2.27; P=0.03) remained a significant predictor. When the data were evaluated according to the absence of coronary artery disease, as compared with the presence of any coronary artery disease, the odds ratios were slightly smaller, but in general, the trends described were maintained, so that younger patients had higher odds ratios than older patients.Correlations between Oxidized LDL Levels and Other Biomarkers
Levels of LDL cholesterol were weakly associated with levels of Lp(a) lipoprotein (r=0.17, P<0.001), and with the oxidized phospholipid:apo B-100 ratio (r=0.09, P=0.05). CRP levels correlated weakly with LDL cholesterol levels (r=0.10, P=0.02) and triglyceride levels (r=0.11, P=0.01). There were no significant correlations between the oxidized phospholipid:apo B-100 ratio or Lp(a) lipoprotein levels and CRP levels, age, body-mass index, blood pressure, and serum creatinine level.
Discussion
This study shows an association between the oxidized phospholipid:apo B-100 ratio in plasma and the presence and extent of angiographically documented coronary artery disease. The association is independent of all clinical and lipid-related risk factors, except one, Lp(a) lipoprotein, which also has a strong association with angiographically documented coronary artery disease. The odds ratios for angiographically documented coronary artery disease associated with the Lp(a) lipoprotein level were nearly identical with those associated with the oxidized phospholipid:apo B-100 ratio. However, among patients younger than 60 years of age, the oxidized phospholipid:apo B-100 ratio remained an independent predictor of obstructive coronary artery disease. There was a strong correlation between levels of Lp(a) lipoprotein and the oxidized phospholipid:apo B-100 ratio. These observations, in conjunction with previous studies from our laboratory showing that in plasma such oxidized phospholipids are predominantly physically present on Lp(a) lipoprotein,5-7,9 as opposed to other lipoproteins, lend strong support to the hypothesis that, in the setting of enhanced oxidative stress, proinflammatory oxidized phospholipids may, in part, mediate the atherogenicity of Lp(a) lipoprotein.
The natural murine monoclonal IgM autoantibody E06, cloned from apolipoprotein E-receptor–deficient mice,12 is functionally identical with classic natural T15 murine antibodies that bind phosphorylcholine on the cell-wall polysaccharide of pathogens such as pneumococcus and provide optimal protection from pneumococcal infections.13 In vitro, E06 binds to and prevents the uptake of oxidized LDL and apoptotic cells by scavenger receptors of macrophages. Binder et al. have also shown that the immunization of mice with Streptococcus pneumoniae results in increased titers of IgM oxidized LDL autoantibodies and reduction in the progression of atherosclerosis.14,15 These observations suggest that seemingly unrelated proatherogenic processes, such as oxidation, apoptosis, and infection, share molecular mimicry of the phosphorylcholine epitopes found on proinflammatory oxidized phospholipids.16
Although previous studies have shown that plasma oxidized LDL levels are elevated in patients with clinically manifest stable coronary artery disease17,18 and acute coronary syndromes,2,4,5,19 our study shows that oxidized phospholipids present on particles of apo B-100 and primarily on Lp(a) lipoprotein correlate with both the presence and extent of angiographically documented coronary artery disease. Although most of the oxidized LDL is present within the vessel wall,20 this study suggests that the small amounts of minimally modified LDL (e.g., particles of apo B-100 that contain oxidized phospholipids) are present in the circulation. This finding is also consistent with previous studies from our laboratory showing that the oxidized phospholipid:apo B-100 ratio (with oxidized LDL measured with use of antibody E06) rises abruptly after acute coronary events5 and immediately after percutaneous coronary intervention6 — situations in which the release of oxidized phospholipids (or oxidized LDL, or both) from the vessel wall might be postulated.
A potential pathophysiological relationship between levels of oxidized phospholipids and Lp(a) lipoprotein is strongly supported by this study and by data from earlier studies from our laboratory showing that oxidized phospholipids are physically associated with Lp(a) lipoprotein5-7 bound to lysine residues on isolated fragments of kringle V of apolipoprotein(a)9 and also in the lipid phase of Lp(a) lipoprotein (unpublished data). In addition, the kringle V fragments containing such oxidized phospholipids induce inflammatory responses by up-regulating secretion of interleukin-8 by cultured human macrophages.9,21
In this study, we have shown that the predictive abilities of levels of oxidized LDL and Lp(a) lipoprotein for obstructive coronary artery disease are highly interdependent. In the entire study group, when Lp(a) lipoprotein was excluded from the multivariable analysis, the odds ratios for the oxidized phospholipid:apo B-100 ratio were similar to those for traditional risk factors such as age, hypertension, and LDL cholesterol. Similarly, without the oxidized phospholipid:apo B-100 ratio in the analysis, Lp(a) lipoprotein levels stood as an independent predictor, as has been shown in a recent meta-analysis.8 In the entire study group, with the oxidized phospholipid:apo B-100 ratio in the model, there was no added ability of Lp(a) lipoprotein levels to explain the risk of obstructive coronary artery disease, suggesting that measures of oxidized LDL and Lp(a) lipoprotein represent a common path of biologic influence on the risk for coronary artery disease. However, in patients 60 years of age or younger, the oxidized phospholipid:apo B-100 ratio maintained its independent predictive power even with Lp(a) lipoprotein in the model. This observation supports the hypothesis that much of the risk attributable to Lp(a) lipoprotein levels can be explained by the binding of oxidized phospholipids by Lp(a) lipoprotein, but that in younger patients, an additional risk associated with oxidized phospholipids may be present, perhaps through proinflammatory pathways independent of Lp(a) lipoprotein.
The physiologic role of Lp(a) lipoprotein is unknown. We and others have suggested that a potential physiologic role of Lp(a) lipoprotein may be to bind and detoxify proinflammatory oxidized phospholipids.5-7,22 Lp(a) lipoprotein, which is present only in humans and Old World primates (although a partially related gene arose separately in hedgehogs), may have evolved to provide protection against various oxidative stressors. For example, Lp(a) lipoprotein has been shown to be involved in wound healing23 and possibly in preventing angiogenesis in tumor models,24 and elevated levels have been noted in centenarians in a manner consistent with human longevity.25
Similarly, oxidized phospholipids are generated not only during atherogenesis but also in inflammation and apoptosis,13,26 which suggests that housekeeping functions involving the clearance of such oxidized phospholipids may have evolved for maintaining general health as well as vascular health. In this regard, Lp(a) lipoprotein may act in a way similar to CRP, which Chang et al. have shown also binds specifically to the phosphorylcholine moiety of oxidized phospholipids and apoptotic cells.27 Indeed, we and others have shown that Lp(a) lipoprotein acts as an acute-phase reactant in patients with acute coronary syndromes.5,6,28 It has also been reported to be highly enriched (higher by a factor of 7 than LDL) in platelet-activating factor acetyl hydrolase,29,30 an enzyme that potentially could detoxify such oxidized phospholipids by removing the oxidized fatty acid.
Thus, when present at low levels, Lp(a) lipoprotein may serve a protective function by binding and participating in the transfer and possible degradation of oxidized phospholipids formed during normal homeostasis or in acutely stressful situations. However, when Lp(a) lipoprotein levels are chronically elevated (as determined genetically), especially in a milieu of chronically increased oxidative stress, Lp(a) lipoprotein, with its content of oxidized phospholipids, may be proatherogenic, particularly since it has enhanced binding to the extracellular matrix of the artery wall.31-33
The association between the oxidized phospholipid:apo B-100 ratio and angiographically documented coronary artery disease in our study was much stronger for patients 60 years of age or younger than for older patients. The reasons for this association are not entirely clear, but many previous studies have documented a strikingly similar relationship between Lp(a) lipoprotein levels and angiographically documented disease among younger patients only.34-40 By excluding patients with diabetes and previous coronary revascularization from our study, we may have preferentially enriched the study group with younger patients with fewer traditional risk factors. In addition, increasing age, which is a surrogate for known and unknown risk factors, is itself one of the strongest risk factors for coronary artery disease. Thus, the independent effects of oxidized LDL and Lp(a) lipoprotein levels appear to diminish with age, presumably because of the cumulative contributions of additional risk factors that affect the clinical expression of atherosclerosis.
The limitations of this study include the fact that angiography is not a precise method for quantifying atherosclerosis. In addition, we have not yet defined the exact oxidized phospholipids, their physical location within Lp(a) lipoprotein, or the rates of flux, binding, and removal of oxidized phospholipids that are on Lp(a) lipoprotein.
In conclusion, we have documented that plasma levels of oxidized phospholipids present on apo B-100–containing lipoproteins and predominantly on Lp(a) lipoprotein reflect the presence and extent of angiographically documented coronary artery disease. We propose that in settings of enhanced oxidative stress and elevated Lp(a) lipoprotein levels, a proinflammatory milieu may predominate that contributes to the clinical expression of cardiovascular disease. Further studies are needed to explore these mechanisms and to determine whether these measures of oxidation predict clinical events.
Supported by grants from the La Jolla Specialized Center of Research in Molecular Medicine and Atherosclerosis (HL56989), the National Heart, Lung, and Blood Institute (HL69646, HL57505), the Donald W. Reynolds Foundation, and the Mayo Foundation.
Dr. Tsimikas reports having served as a consultant to and on the speakers' bureau of Pfizer and General Electric and having received investigator-initiated grants from these companies. Dr. Witztum reports having served as a consultant to AtheroGenics and on the speakers' bureau of Merck. Dr. Berger reports having received research funding and honoraria from Aventis, Bristol-Myers Squib, and Sanofi and having served on scientific advisory boards for Genentech and Johnson & Johnson. Dr. Kornman is an employee of Interleukin Genetics and reports holding equity in the company. Dr. McConnell reports having received grant support from diaDexus. A patent for the potential use of the E06 antibody has been awarded to the University of California in the names of Dr. Witztum and colleagues and has been licensed by the University of California to AtheroGenics.
We are indebted to Claes Bergmark for advice on this project.
Source Information
From the Divisions of Cardiovascular Diseases (S.T.) and Endocrinology and Metabolism (E.R.M., J.L.W.), University of California, San Diego; the Division of Cardiovascular Diseases (E.S.B.), the Department of Laboratory Medicine and Pathology (J.P.M.), and the Division of Biostatistics (R.J.L.), Mayo Clinic, Rochester, Minn.; Interleukin Genetics, Waltham, Mass. (K.S.K.); and the Division of Cardiovascular Diseases, Duke Clinical Research Institute, Durham, N.C. (P.B.B.).
Address reprint requests to Dr. Tsimikas at the Vascular Medicine Program, University of California, San Diego, 9500 Gilman Dr., Basic Sciences Bldg., Rm. 1080, La Jolla, CA 92093-0682, or at stsimikas@ucsd.edu.
- References
References
1
Tsimikas S ,Witztum JL . Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation 2001;103:1930-1932
Web of Science | Medline2
Ehara S ,Ueda M ,Naruko T , et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001;103:1955-1960
Web of Science | Medline3
Holvoet P ,Collen D ,Van de Werf F . Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 1999;281:1718-1721
CrossRef | Web of Science | Medline4
Nishi K ,Itabe H ,Uno M , et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002;22:1649-1654
CrossRef | Web of Science | Medline5
Tsimikas S ,Bergmark C ,Beyer RW , et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003;41:360-370
CrossRef | Web of Science | Medline6
Tsimikas S ,Lau HK ,Han KR , et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 2004;109:3164-3170
CrossRef | Web of Science | Medline7
Tsimikas S ,Witztum JL ,Miller ER , et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004;110:1406-1412
CrossRef | Web of Science | Medline8
Danesh J ,Collins R ,Peto R . Lipoprotein(a) and coronary artery disease: meta-analysis of prospective studies. Circulation 2000;102:1082-1085
Web of Science | Medline9
Edelstein C ,Pfaffinger D ,Hinman J , et al. Lysine-phosphatidylcholine adducts in Kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 2003;278:52841-52847
CrossRef | Web of Science | Medline10
Wolk R ,Berger P ,Lennon RJ ,Brilakis ES ,Somers VK . Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation 2003;108:2206-2211
CrossRef | Web of Science | Medline11
McConnell JP ,Branum EL ,Ballman KV ,Lagerstedt SA ,Katzmann JA ,Jaffe AS . Gender differences in C-reactive protein concentrations -- confirmation with two sensitive methods. Clin Chem Lab Med 2002;40:56-59
CrossRef | Web of Science | Medline12
Palinski W ,Horkko S ,Miller E , et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice: demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996;98:800-814
CrossRef | Web of Science | Medline13
Shaw PX ,Horkko S ,Chang MK , et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000;105:1731-1740
CrossRef | Web of Science | Medline14
Binder CJ ,Horkko S ,Dewan A , et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003;9:736-743
CrossRef | Web of Science | Medline15
Binder CJ ,Hartvigsen K ,Chang MK , et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004;114:427-437
Web of Science | Medline16
Binder CJ ,Chang MK ,Shaw PX , et al. Innate and acquired immunity in atherogenesis. Nat Med 2002;8:1218-1226
CrossRef | Web of Science | Medline17
Toshima S ,Hasegawa A ,Kurabayashi M , et al. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20:2243-2247
CrossRef | Web of Science | Medline18
Holvoet P ,Mertens A ,Verhamme P , et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:844-848
CrossRef | Web of Science | Medline19
Holvoet P ,Vanhaecke J ,Janssens S ,Van de Werf F ,Collen D . Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998;98:1487-1494
Web of Science | Medline20
Tsimikas S, Glass C, Steinberg D, Witztum JL. Lipoproteins, lipoprotein oxidation and atherogenesis. In: Chien KR, ed. Molecular basis of cardiovascular disease: a companion to Braunwald's Heart Disease. Philadelphia: W.B. Saunders, 2004:385-413.
21
Klezovitch O ,Edelstein C ,Scanu AM . Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a): evidence for a critical involvement of elements in its C-terminal domain. J Biol Chem 2001;276:46864-46869
CrossRef | Web of Science | Medline22
Hobbs HH ,White AL . Lipoprotein(a): intrigues and insights. Curr Opin Lipidol 1999;10:225-236
CrossRef | Web of Science | Medline23
Yano Y ,Shimokawa K ,Okada Y ,Noma A . Immunolocalization of lipoprotein(a) in wounded tissues. J Histochem Cytochem 1997;45:559-568
CrossRef | Web of Science | Medline24
Trieu VN ,Uckun FM . Apolipoprotein(a), a link between atherosclerosis and tumor angiogenesis. Biochem Biophys Res Commun 1999;257:714-718
CrossRef | Web of Science | Medline25
Thillet J ,Doucet C ,Chapman J ,Herbeth B ,Cohen D ,Faure-Delanef L . Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity: evidence from a large population of French centenarians. Atherosclerosis 1998;136:389-394
CrossRef | Web of Science | Medline26
Chang MK ,Binder CJ ,Miller YI , et al. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 2004;200:1359-1370
CrossRef | Web of Science | Medline27
Chang MK ,Binder CJ ,Torzewski M ,Witztum JL . C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 2002;99:13043-13048
CrossRef | Web of Science | Medline28
Maeda S ,Abe A ,Seishima M ,Makino K ,Noma A ,Kawade M . Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989;78:145-150
CrossRef | Web of Science | Medline29
Blencowe C ,Hermetter A ,Kostner GM ,Deigner HP . Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein(a) in comparison with low density lipoprotein. J Biol Chem 1995;270:31151-31157
CrossRef | Web of Science | Medline30
Karabina SA ,Liapikos TA ,Grekas G ,Goudevenos J ,Tselepis AD . Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim Biophys Acta 1994;1213:34-38
Web of Science | Medline31
Dangas G ,Mehran R ,Harpel PC , et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998;32:2035-2042
CrossRef | Web of Science | Medline32
Cushing GL ,Gaubatz JW ,Nava ML , et al. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989;9:593-603
CrossRef | Medline33
Berg K ,Dahlen G ,Christophersen B ,Cook T ,Kjekshus J ,Pedersen T . Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997;52:254-261
CrossRef | Web of Science | Medline34
Hearn JA ,DeMaio SJ Jr ,Roubin GS ,Hammarstrom M ,Sgoutas D . Predictive value of lipoprotein(a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease. Am J Cardiol 1990;66:1176-1180
CrossRef | Web of Science | Medline35
Sandkamp M ,Funke H ,Schulte H ,Kohler E ,Assmann G . Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990;36:20-23
Web of Science | Medline36
Foody JM ,Milberg JA ,Robinson K ,Pearce GL ,Jacobsen DW ,Sprecher DL . Homocysteine and lipoprotein(a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 2000;20:493-499
CrossRef | Web of Science | Medline37
Rhoads GG ,Dahlen G ,Berg K ,Morton NE ,Dannenberg AL . Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986;256:2540-2544
CrossRef | Web of Science | Medline38
Dahlen GH ,Guyton JR ,Attar M ,Farmer JA ,Kautz JA ,Gotto AM Jr . Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758-765
CrossRef | Web of Science | Medline39
Sunayama S ,Daida H ,Mokuno H , et al. Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women > or = 55 years of age. Circulation 1996;94:1263-1268
Web of Science | Medline40
Assmann G ,Schulte H ,von Eckardstein A . Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77:1179-1184
CrossRef | Web of Science | Medline
- Citing Articles (143)
Citing Articles
1
Karen C. Briley-Saebo, Tuyen Hoang Nguyen, Alexander M. Saeboe, Young-Seok Cho, Sung Kee Ryu, Eugenia Volkava, Stephen Dickson, Gregor Leibundgut, Philipp Weisner, Simone Green, Florence Casanada, Yury I. Miller, Walter Shaw, Joseph L. Witztum, Zahi A. Fayad, Sotirios Tsimikas. (2012) In Vivo Detection of Oxidation-Specific Epitopes in Atherosclerotic Lesions Using Biocompatible Manganese Molecular Magnetic Imaging Probes. Journal of the American College of Cardiology 59:6, 616-626
CrossRef2
Monica Farkas-Epperson, Ngoc-Anh Le. (2012) Lipoproteins as biosensors of endothelial oxidative status. Clinical Lipidology 7:1, 49-63
CrossRef3
Nidhi Gupta, K.B.K. Binu, Surjit Singh, Nagarjuna V. Maturu, Yash P. Sharma, Anil Bhansali, Kiran Dip Gill. (2012) Low Serum PON1 Activity: An Independent Risk Factor for Coronary Artery Disease in North- West Indian Type 2 Diabetics. Gene
CrossRef4
Christopher T. Avetta, Berkeley J. Shorthill, Chun Ren, Timothy E. Glass. (2012) Molecular Tubes for Lipid Sensing: Tube Conformations Control Analyte Selectivity and Fluorescent Response. The Journal of Organic Chemistry120110120608008
CrossRef5
Matthew Konerman, Krishnaji Kulkarni, Peter P. Toth, Steven R. Jones. (2012) Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients defining four physiologically discrete groups. Journal of Clinical Lipidology
CrossRef6
Xianhai Huang, Jing Su, Ashwin U. Rao, Haiqun Tang, Wei Zhou, Xiaohong Zhu, Xiao Chen, Zhidan Liu, Ying Huang, Sylvia Degrado, Dong Xiao, Jun Qin, Robert Aslanian, Brian A. McKittrick, Scott Greenfeder, Margaret van Heek, Madhu Chintala, Anandan Palani. (2012) SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist. Bioorganic & Medicinal Chemistry Letters 22:2, 854-858
CrossRef7
Anne von Zychlinski, Torsten Kleffmann, Michael J.A. Williams, Sally P. McCormick. (2011) Proteomics of Lipoprotein(a) identifies a protein complement associated with response to wounding. Journal of Proteomics 74:12, 2881-2891
CrossRef8
Pamela Song, Jin Myoung Seok, Wook Sung Kim, Young Tak Lee, Duk-Kyung Kim, Gyeong-Moon Kim. (2011) Increased lipoprotein(a) is associated with polyvascular disease in patients undergoing coronary artery bypass graft. Atherosclerosis 219:1, 285-290
CrossRef9
Jeppe Hagstrup Christensen, Erik Berg Schmidt, My Svensson. (2011) n-3 polyunsaturated fatty acids, lipids and lipoproteins in end-stage renal disease. Clinical Lipidology 6:5, 563-576
CrossRef10
Adam Taleb, Joseph L Witztum, Sotirios Tsimikas. (2011) Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomarkers in Medicine 5:5, 673-694
CrossRef11
Koichi Sugamura, John F. Keaney,. (2011) Reactive oxygen species in cardiovascular disease. Free Radical Biology and Medicine 51:5, 978-992
CrossRef12
Yuan Zhao, Yushui Ma, Ying Fang, Lili Liu, Shengdi Wu, Da Fu, Xiaofeng Wang. (2011) Association between PON1 activity and coronary heart disease risk: A meta-analysis based on 43 studies. Molecular Genetics and Metabolism
CrossRef13
Matthew Konerman, Krishnaji Kulkarni, Peter P. Toth, Steven R. Jones. (2011) Evidence of dependence of lipoprotein(a) on triglyceride and high-density lipoprotein metabolism. Journal of Clinical Lipidology
CrossRef14
Byambaa Enkhmaa, Erdembileg Anuurad, Zeynep Ozturk, Wei Zhang, Thomas A. Pearson, Lars Berglund. (2011) Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians. Translational Research 158:2, 92-98
CrossRef15
L. Fernández-Murga, J.J. Tarín, M.A. García-Perez, A. Cano. (2011) The impact of chocolate on cardiovascular health. Maturitas 69:4, 312-321
CrossRef16
Kagehiro Uchida, Akira Suehiro, Mamoru Nakanishi, Tatsuya Sawamura, Ichiro Wakabayashi. (2011) Associations of atherosclerotic risk factors with oxidized low-density lipoprotein evaluated by LOX-1 ligand activity in healthy men. Clinica Chimica Acta 412:17-18, 1643-1647
CrossRef17
Byambaa Enkhmaa, Erdembileg Anuurad, Wei Zhang, Tina Tran, Lars Berglund. (2011) Lipoprotein(a): Genotype–Phenotype Relationship and Impact on Atherogenic Risk. Metabolic Syndrome and Related Disorders110712062212003
CrossRef18
Marit S. Nenseter, Henriette Walaas Lindvig, Thor Ueland, Gisle Langslet, Leiv Ose, Kirsten B. Holven, Kjetil Retterstøl. (2011) Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia. Atherosclerosis 216:2, 426-432
CrossRef19
J. Kosola, M. Ahotupa, H. Kyröläinen, M. Santtila, T. Vasankari. (2011) Both poor cardiorespiratory and weak muscle fitness are related to a high concentration of oxidized low-density lipoprotein lipids. Scandinavian Journal of Medicine & Science in Sportsno-no
CrossRef20
Guglielmina Chimienti, Anna Mezzapesa, Grazia M. Liuzzi, Tiziana Latronico, Gabriella Pepe. (2011) Apolipoprotein(a) inhibits lipopolysaccharide-induced IL-6 secretion in human astrocytoma cell line by interfering with lipopolysaccharide signaling. Inflammation Research 60:4, 329-335
CrossRef21
Esther Merki, Mark Graham, Adam Taleb, Gregor Leibundgut, Xiaohong Yang, Elizabeth R. Miller, Wuxia Fu, Adam E. Mullick, Richard Lee, Peter Willeit, Rosanne M. Crooke, Joseph L. Witztum, Sotirios Tsimikas. (2011) Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice. Journal of the American College of Cardiology 57:15, 1611-1621
CrossRef22
Markus Zutt, Ulrich Krüger, Albert Rosenberger, Michael P. Schön, Christine Neumann, Nico von Ahsen, Lutz Kretschmer. (2011) Increased Lipoprotein (a) concentrations in patients with chronic venous leg ulcers: a study on patients with or without postthrombotic syndrome. Wound Repair and Regeneration 19:2, 168-172
CrossRef23
Maureen McMahon, Bevra H Hahn, Brian J Skaggs. (2011) Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Review of Clinical Immunology 7:2, 227-241
CrossRef24
Margrit Schwarz, Jae B. Kim. 2011. Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL. , 199-234.
CrossRef25
Nongnuch Sirachainan, Chalermkwan Chaiyong, Anannit Visudtibhan, Werasak Sasanakul, Seksit Osatakul, Pakawan Wongwerawattanakoon, Praguywan Kadegasem, Ampaiwan Chuansumrit. (2011) Lipoprotein(a) and the risk of thromboembolism in Thai children. Thrombosis Research 127:2, 100-104
CrossRef26
Kazuhiko Kotani, Shingo Yamada, Toshiyuki Yamada, Nobuyuki Taniguchi, Ikunosuke Sakurabayashi. (2011) The relationship between oxidized lipoprotein(a) and carotid atherosclerosis in asymptomatic subjects: A comparison with native lipoprotein(a). Lipids in Health and Disease 10:1, 174
CrossRef27
Hiroyuki Itabe, Takashi Obama, Rina Kato. (2011) The Dynamics of Oxidized LDL during Atherogenesis. Journal of Lipids 2011, 1-9
CrossRef28
Valentina Kon, MacRae F. Linton, Sergio Fazio. (2011) Atherosclerosis in chronic kidney disease: the role of macrophages. Nature Reviews Nephrology 7:1, 45-54
CrossRef29
Karen C. Briley-Saebo, Young Seok Cho, Peter X. Shaw, Sung Kee Ryu, Venkatesh Mani, Stephen Dickson, Ehsan Izadmehr, Simone Green, Zahi A. Fayad, Sotirios Tsimikas. (2011) Targeted Iron Oxide Particles for In Vivo Magnetic Resonance Detection of Atherosclerotic Lesions With Antibodies Directed to Oxidation-Specific Epitopes. Journal of the American College of Cardiology 57:3, 337-347
CrossRef30
Jun-jun Wang, Jian-bin Gong, Han-qing Li, Dong-mei Niu, Ai-zhong Han, Jia Wu, Chun-ni Zhang. (2011) Lipoprotein(a) Complexes with Beta2-Glycoprotein I in Patients with Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis
CrossRef31
Juan A. Gómez Gerique. (2010) Factores de riesgo emergentes. Clínica e Investigación en Arteriosclerosis 22, 54-57
CrossRef32
Erdembileg Anuurad, Byambaa Enkhmaa, Lars Berglund. (2010) Enigmatic Role of Lipoprotein(a) in Cardiovascular Disease. Clinical and Translational Science 3:6, 327-332
CrossRef33
B. G. Nordestgaard, M. J. Chapman, K. Ray, J. Boren, F. Andreotti, G. F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O. S. Descamps, E. Fisher, P. T. Kovanen, J. A. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, M.-R. Taskinen, L. Tokgozoglu, A. Tybjaerg-Hansen, . (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal 31:23, 2844-2853
CrossRef34
M. Rizzo, K. Berneis, S. Koulouris, S. Pastromas, G. B. Rini, D. Sakellariou, A. S. Manolis. (2010) Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?. International Journal of Clinical Practice 64:12, 1632-1642
CrossRef35
B.S. Kim, H.S. Jung, O.Y. Bang, C.S. Chung, K.H. Lee, G.M. Kim. (2010) Elevated serum lipoprotein(a) as a potential predictor for combined intracranial and extracranial artery stenosis in patients with ischemic stroke. Atherosclerosis 212:2, 682-688
CrossRef36
Sotirios Tsimikas, Ziad Mallat, Philippa J. Talmud, John J.P. Kastelein, Nicholas J. Wareham, Manjinder S. Sandhu, Elizabeth R. Miller, Joelle Benessiano, Alain Tedgui, Joseph L. Witztum, Kay-Tee Khaw, S. Matthijs Boekholdt. (2010) Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events. Journal of the American College of Cardiology 56:12, 946-955
CrossRef37
Vasiliki Katsi, Dimitris Tousoulis, Evangelos Chatzistamatiou, Emmanouil Androulakis, Georgios Moustakas, Ioannis Skiadas, Constantinos Tsioufis, Charalambos Antoniades, Christodoulos I. Stefanadis, Ioannis E. Kallikazaros. (2010) A 31 year old woman with essential hypertension grade III and branch retinal vein occlusion with homozygous C677T MTHFR hyperhomocysteinemia and high Lp(a) levels. International Journal of Cardiology 143:3, e42-e44
CrossRef38
Jun-jun Wang, Chun-ni Zhang, Ai-zhong Han, Jian-bin Gong, Ke Li. (2010) Percutaneous coronary intervention results in acute increases in native and oxidized lipoprotein(a) in patients with acute coronary syndrome and stable coronary artery disease. Clinical Biochemistry 43:13-14, 1107-1111
CrossRef39
Pia R. Kamstrup. (2010) Lipoprotein(a) and ischemic heart disease—A causal association? A review. Atherosclerosis 211:1, 15-23
CrossRef40
M. John Chapman, Jan S. Redfern, Mark E. McGovern, Philippe Giral. (2010) Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 126:3, 314-345
CrossRef41
Sonia-Athina Karabina, Sarah Gora, Rajai Atout, Ewa Ninio. (2010) Extracellular phospholipases in atherosclerosis. Biochimie 92:6, 594-600
CrossRef42
Courtney B. Sherman, Stephen J. Peterson, William H. Frishman. (2010) Apolipoprotein A-I Mimetic Peptides. Cardiology in Review 18:3, 141-147
CrossRef43
Valmore Bermúdez, Nailet Arráiz, Daniel Aparicio, Edward Rojas, Daniela Gotera, Xavier Guerra, Roger Canelón, Judith Faría, Luis Sorell, Anilsa Amell, Nadia Reyna, Mayela Cabrera, Edgardo Mengual, Raquel Cano, Clímaco Cano, Manuel Velasco. (2010) Lipoprotein(a): From Molecules to Therapeutics. American Journal of Therapeutics 17:3, 263-273
CrossRef44
Nosratola D. Vaziri, Mohamad Navab, Alan M. Fogelman. (2010) HDL metabolism and activity in chronic kidney disease. Nature Reviews Nephrology 6:5, 287-296
CrossRef45
Jun-jun Wang, Ai-zhong Han, Yang Meng, Jian-bin Gong, Chun-ni Zhang, Ke Li, Yu-Xiu Liu. (2010) Measurement of oxidized lipoprotein (a) in patients with acute coronary syndromes and stable coronary artery disease by 2 ELISAs: Using different capture antibody against oxidized lipoprotein (a) or oxidized LDL. Clinical Biochemistry 43:6, 571-575
CrossRef46
Kiyohito Arai, May M. Luke, Marlys L. Koschinsky, Elizabeth R. Miller, Clive R. Pullinger, Joseph L. Witztum, John P. Kane, Sotirios Tsimikas. (2010) The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis 209:2, 498-503
CrossRef47
Loren F. Hiratzka, George L. Bakris, Joshua A. Beckman, Robert M. Bersin, Vincent F. Carr, Donald E. Casey, Kim A. Eagle, Luke K. Hermann, Eric M. Isselbacher, Ella A. Kazerooni, Nicholas T. Kouchoukos, Bruce W. Lytle, Dianna M. Milewicz, David L. Reich, Souvik Sen, Julie A. Shinn, Lars G. Svensson, David M. Williams. (2010) 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. Journal of the American College of Cardiology 55:14, e27-e129
CrossRef48
Naser Ahmadi, Sotirios Tsimikas, Fereshteh Hajsadeghi, Anila Saeed, Vahid Nabavi, Manzoor A. Bevinal, Jigar Kadakia, Ferdinand Flores, Ramin Ebrahimi, Matthew J. Budoff. (2010) Relation of Oxidative Biomarkers, Vascular Dysfunction, and Progression of Coronary Artery Calcium. The American Journal of Cardiology 105:4, 459-466
CrossRef49
Kathiresan, Sekar, . (2009) Lp(a) Lipoprotein Redux — From Curious Molecule to Causal Risk Factor. New England Journal of Medicine 361:26, 2573-2574
Full Text50
Clarke, Robert, Peden, John F., Hopewell, Jemma C., Kyriakou, Theodosios, Goel, Anuj, Heath, Simon C., Parish, Sarah, Barlera, Simona, Franzosi, Maria Grazia, Rust, Stephan, Bennett, Derrick, Silveira, Angela, Malarstig, Anders, Green, Fiona R., Lathrop, Mark, Gigante, Bruna, Leander, Karin, de Faire, Ulf, Seedorf, Udo, Hamsten, Anders, Collins, Rory, Watkins, Hugh, Farrall, Martin, . (2009) Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease. New England Journal of Medicine 361:26, 2518-2528
Full Text51
Andrea M. Vincent, Lucy M. Hinder, Rodica Pop-Busui, Eva L. Feldman. (2009) Hyperlipidemia: a new therapeutic target for diabetic neuropathy. Journal of the Peripheral Nervous System 14:4, 257-267
CrossRef52
Jane A. Leopold, Joseph Loscalzo. (2009) Oxidative risk for atherothrombotic cardiovascular disease. Free Radical Biology and Medicine 47:12, 1673-1706
CrossRef53
Barry H. Trachtenberg, Joshua M. Hare. (2009) Biomarkers of Oxidative Stress in Heart Failure. Heart Failure Clinics 5:4, 561-577
CrossRef54
Jun-jun Wang, Chun-ni Zhang, Yang Meng, Ai-zhong Han, Jian-bin Gong, Ke Li. (2009) Elevated concentrations of oxidized lipoprotein(a) are associated with the presence and severity of acute coronary syndromes. Clinica Chimica Acta 408:1-2, 79-82
CrossRef55
Pia R Kamstrup, Børge G Nordestgaard. (2009) Lipoprotein(a) should be taken much more seriously. Biomarkers in Medicine 3:5, 439-441
CrossRef56
Wei Liu, Jason D. Morrow, Huiyong Yin. (2009) Quantification of F2-isoprostanes as a reliable index of oxidative stress in vivo using gas chromatography–mass spectrometry (GC-MS) method. Free Radical Biology and Medicine 47:8, 1101-1107
CrossRef57
Junjun Wang, Bing Hu, Yang Meng, Chunni Zhang, Ke Li, Cai Hui. (2009) The level of malondialdehyde-modified LDL and LDL immune complexes in patients with rheumatoid arthritis. Clinical Biochemistry 42:13-14, 1352-1357
CrossRef58
Junjun Wang, Dongmei Niu, Yang Meng, Aizhong Han, Ke Li, Chunni Zhang. (2009) Plasma oxidized lipoprotein(a) and its immune complexes are present in newborns and children. Clinica Chimica Acta 407:1-2, 1-5
CrossRef59
Matthew J. Budoff, Naser Ahmadi, Khawar M. Gul, Sandy T. Liu, Ferdinand R. Flores, Jima Tiano, Junichiro Takasu, Elizabeth Miller, Sotirios Tsimikas. (2009) Aged garlic extract supplemented with B vitamins, folic acid and l-arginine retards the progression of subclinical atherosclerosis: A randomized clinical trial. Preventive Medicine 49:2-3, 101-107
CrossRef60
Konstantinos Tziomalos, Vasilios G Athyros, Anthony S Wierzbicki, Dimitri P Mikhailidis. (2009) Lipoprotein a: where are we now?. Current Opinion in Cardiology 24:4, 351-357
CrossRef61
Alexander E. Fraley, Gregory G. Schwartz, Anders G. Olsson, Scott Kinlay, Michael Szarek, Nader Rifai, Peter Libby, Peter Ganz, Joseph L. Witztum, Sotirios Tsimikas. (2009) Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low-Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology 53:23, 2186-2196
CrossRef62
Mohammad Z. Ashraf, Niladri S. Kar, Eugene A. Podrez. (2009) Oxidized phospholipids: Biomarker for cardiovascular diseases. The International Journal of Biochemistry & Cell Biology 41:6, 1241-1244
CrossRef63
Scott Mintzer, Christopher T. Skidmore, Caitlin J. Abidin, Megan C. Morales, Inna Chervoneva, David M. Capuzzi, Michael R. Sperling. (2009) Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Annals of Neurology 65:4, 448-456
CrossRef64
Miquel Gómez, Vicente Valle, Fernando Arós, Ginés Sanz, Joan Sala, Miquel Fiol, Jordi Bruguera, Roberto Elosua, Lluís Molina, Helena Martí, M. Isabel Covas, Andrés Rodríguez-Llorián, Montserrat Fitó, Miguel A. Suárez-Pinilla, Rocío Amezaga, Jaume Marrugat. (2009) LDL oxidada, lipoproteína(a) y otros factores de riesgo emergentes en el infarto agudo de miocardio (estudio FORTIAM). Revista Española de Cardiología 62:4, 373-382
CrossRef65
Daniel I. Chasman, Dov Shiffman, Robert Y.L. Zee, Judy Z. Louie, May M. Luke, Charles M. Rowland, Joseph J. Catanese, Julie E. Buring, James J. Devlin, Paul M. Ridker. (2009) Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 203:2, 371-376
CrossRef66
Sergio López, Almudena Ortega, Lourdes Varela, Beatriz Bermúdez, Francisco JG Muriana, Rocío Abia. (2009) Recent advances in lipoprotein and atherosclerosis: A nutrigenomic approach. Grasas y Aceites 60:1,
CrossRef67
Ngoc-Anh Le. (2009) Oxidized lipids and lipoproteins: indices of risk or targets for management. Clinical Lipidology 4:1, 41-54
CrossRef68
Diana M. Stafforini. (2009) Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2). Cardiovascular Drugs and Therapy 23:1, 73-83
CrossRef69
Mònica Guxens, Montserrat Fitó, Miguel-Angel Martínez-González, Jordi Salas-Salvadó, Ramón Estruch, Ernest Vinyoles, Miguel Fiol, Dolores Corella, Fernando Arós, Enrique Gómez-Gracia, Valentina Ruiz-Gutiérrez, José Lapetra, Emili Ros, Joan Vila, María-Isabel Covas. (2009) Hypertensive Status and Lipoprotein Oxidation in an Elderly Population at High Cardiovascular Risk. American Journal of Hypertension 22:1, 68-73
CrossRef70
Hiroyuki Itabe. (2009) Circulating oxidized lipoproteins and cardiovascular risk. Current Cardiovascular Risk Reports 3:1, 18-22
CrossRef71
Sayoko Ogura, Akemi Kakino, Yuko Sato, Yoshiko Fujita, Shin Iwamoto, Kazunori Otsui, Ryo Yoshimoto, Tatsuya Sawamura. (2009) LOX-1. Circulation Journal 73:11, 1993-1999
CrossRef72
Jang Won Son, Hyuk Sang Kwon. (2009) Clinical Implications of Serum Biomarkers in Diabetic Cardiovascular Complications. Korean Diabetes Journal 33:5, 363
CrossRef73
Paul Holvoet, Dieuwke De Keyzer, David R Jacobs Jr. (2008) Oxidized LDL and the metabolic syndrome. Future Lipidology 3:6, 637-649
CrossRef74
Ken Ogasawara, Shinichi Mashiba, Hideki Hashimoto, Shiho Kojima, Shunsuke Matsuno, Motohiro Takeya, Kazuo Uchida, Junji Yajima. (2008) Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clinica Chimica Acta 397:1-2, 42-47
CrossRef75
Adriana Rojas-Villarraga, Oscar-Danilo Ortega-Hernandez, Luis F. Gomez, Aryce L. Pardo, Silvia López-Guzmán, Camila Arango-Ferreira, Maria-Eugenia Hincapie, Juan F. Betancur, Ricardo Pineda-Tamayo, Francisco J. Diaz, Juan-Manuel Anaya. (2008) Risk Factors Associated with Different Stages of Atherosclerosis in Colombian Patients with Rheumatoid Arthritis. Seminars in Arthritis and Rheumatism 38:2, 71-82
CrossRef76
Turgay Celik, Cagdas Yuksel, Atila Iyisoy, Ersoy Isik. (2008) Lipoprotein(a) and coronary artery disease: Ongoing debate. Nutrition, Metabolism and Cardiovascular Diseases 18:7, e33-e34
CrossRef77
Manish P. Ponda, Irina Barash. (2008) Lipid Metabolism in Dialysis Patients-The Story Gets More Complicated. Seminars in Dialysis 21:5, 390-394
CrossRef78
Maureen McMahon, Ernest Brahn. (2008) Inflammatory lipids as a target for therapy in the rheumatic diseases. Expert Opinion on Investigational Drugs 17:8, 1213-1224
CrossRef79
Sotirios Tsimikas, Joseph L Witztum. (2008) The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Current Opinion in Lipidology 19:4, 369-377
CrossRef80
Anand Prasad, Sotirios Tsimikas. (2008) Candidate biomarkers for the detection of coronary plaque destabilization and rupture. Current Atherosclerosis Reports 10:4, 309-317
CrossRef81
Klaus WJ Wahle, Steven D Heys. (2008) Atherosclerosis: cell biology and lipoproteins. Current Opinion in Lipidology 19:4, 435-437
CrossRef82
Seung Hyuk Choi, Andrew Chae, Elizabeth Miller, Michael Messig, Fady Ntanios, Anthony N. DeMaria, Steven E. Nissen, Joseph L. Witztum, Sotirios Tsimikas. (2008) Relationship Between Biomarkers of Oxidized Low-Density Lipoprotein, Statin Therapy, Quantitative Coronary Angiography, and Atheroma Volume. Journal of the American College of Cardiology 52:1, 24-32
CrossRef83
Michele Mietus-Snyder, Ronald M. Krauss. (2008) Lipid metabolism in children and adolescents: Impact on vascular biology. Journal of Clinical Lipidology 2:3, 127-137
CrossRef84
Bonnie Ky, Anne Burke, Sotirios Tsimikas, Megan L. Wolfe, Mahlet G. Tadesse, Philippe O. Szapary, Joseph L. Witztum, Garret A. FitzGerald, Daniel J. Rader. (2008) The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. Journal of the American College of Cardiology 51:17, 1653-1662
CrossRef85
Jane A. Leopold, Joseph Loscalzo. (2008) Oxidative mechanisms and atherothrombotic cardiovascular disease. Drug Discovery Today: Therapeutic Strategies 5:1, 5-13
CrossRef86
Daniel J. Rader, Alan Daugherty. (2008) Translating molecular discoveries into new therapies for atherosclerosis. Nature 451:7181, 904-913
CrossRef87
Shizuya Yamashita, Hideaki HBujo, Hidenori Arai, Mariko Harada-Shiba, Shigeyuki Matsui, Masanori Fukushima, Yasushi Saito, Toru Kita, Yuji Matsuzawa. (2008) Long-Term Probucol Treatment Prevents Secondary Cardiovascular Events: a Cohort Study of Patients with Heterozygous Familial Hypercholesterolemia in Japan. Journal of Atherosclerosis and Thrombosis 15:6, 292-303
CrossRef88
Shoichi Ehara, Takahiko Naruko, Naoya Shirai, Akira Itoh, Eishu Hai, Yoshimi Sugama, Yoshihiro Ikura, Masahiko Ohsawa, Takuhiro Okuyama, Nobuyuki Shirai, Hajime Yamashita, Hiroyuki Itabe, Kazuo Haze, Minoru Yoshiyama, Makiko Ueda. (2008) Small Coronary Calcium Deposits and Elevated Plasma Levels of Oxidized Low Density Lipoprotein are Characteristic of Acute Myocardial Infarction. Journal of Atherosclerosis and Thrombosis 15:2, 75-81
CrossRef89
Athanasios I. Papathanasiou, Evangelia S. Lourida, Loukas D. Tsironis, John A. Goudevenos, Alexandros D. Tselepis. (2008) Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Atherosclerosis 196:1, 289-297
CrossRef90
B. GEERAERT, D. DE KEYZER, P. C. DAVEY, F. CROMBÉ, N. BENHABILÈS, P. HOLVOET. (2007) Oxidized low-density lipoprotein-induced expression of ABCA1 in blood monocytes precedes coronary atherosclerosis and is associated with plaque complexity in hypercholesterolemic pigs. Journal of Thrombosis and Haemostasis 5:12, 2529-2536
CrossRef91
Maureen McMahon, Bevra H Hahn. (2007) Atherosclerosis and systemic lupus erythematosus — mechanistic basis of the association. Current Opinion in Immunology 19:6, 633-639
CrossRef92
Leonidas H. Duntas, Leonard Wartofsky. (2007) Cardiovascular Risk and Subclinical Hypothyroidism: Focus on Lipids and New Emerging Risk Factors. What Is the Evidence?. Thyroid 17:11, 1075-1084
CrossRef93
K Kalantar-Zadeh, J D Kopple, N Kamranpour, A M Fogelman, M Navab. (2007) HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney International 72:9, 1149-1156
CrossRef94
Junjun Wang, Chunni Zhang, Jianbin Gong, Yanfei Zhu, Li Fu, Xiangdong Wang, Ke Li. (2007) Development of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a) by using purified human oxidized lipoprotein(a) autoantibodies as capture antibody. Clinica Chimica Acta 385:1-2, 73-78
CrossRef95
Gunilla Nordin Fredrikson, Alexandru Schiopu, Göran Berglund, Ragnar Alm, Prediman K. Shah, Jan Nilsson. (2007) Autoantibody against the amino acid sequence 661–680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 194:2, e188-e192
CrossRef96
Paul Holvoet, Nancy S. Jenny, Pamela J. Schreiner, Russell P. Tracy, David R. Jacobs. (2007) The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 194:1, 245-252
CrossRef97
Toshio Murase, Minoru Okubo, Michiyo Amemiya-Kudo, Takaki Hiraga, Junko Oka, Masako Shimada, Tomio Igarashi. (2007) Impact of markedly elevated serum lipoprotein(a) levels (≥100 mg/dL) on the risk of coronary heart disease. Metabolism 56:9, 1187-1191
CrossRef98
Subramaniam Pennathur, Jay W. Heinecke. (2007) Oxidative stress and endothelial dysfunction in vascular disease. Current Diabetes Reports 7:4, 257-264
CrossRef99
Riikka Lautamäki, Tapani Rönnemaa, Risto Huupponen, Terho Lehtimäki, Patricia Iozzo, K.E. Juhani Airaksinen, Juhani Knuuti, Pirjo Nuutila. (2007) Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 56:7, 881-886
CrossRef100
Sergio Durán-Barragán, Graciela S Alarcón. (2007) The heart–joints connection: atherosclerosis and inflammation. Expert Review of Clinical Immunology 3:4, 517-529
CrossRef101
Leonard H. Sigal. (2007) Basic Science for the Clinician 44. JCR: Journal of Clinical Rheumatology 13:3, 160-168
CrossRef102
W Verreth, D Keyzer, P C Davey, B Geeraert, A Mertens, M-C Herregods, G Smith, F Desjardins, J-L Balligand, P Holvoet. (2007) Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. British Journal of Pharmacology 151:3, 347-355
CrossRef103
L. Puccetti, A.L. Pasqui, F. Bruni, M. Pastorelli, F. Ciani, A. Palazzuoli, A. Pontani, A. Ghezzi, A. Auteri. (2007) Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment. International Journal of Cardiology 119:1, 41-47
CrossRef104
Yasunori Abe, Myriam Fornage, Chao-yuh Yang, Ngoc-Anh Bui-Thanh, Vance Wise, Hsin-Hung Chen, Gopikishan Rangaraj, Christie M. Ballantyne. (2007) L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion. Atherosclerosis 192:1, 56-66
CrossRef105
Theresa A. Molisse, Paul A. Tunick, Itzhak Kronzon. (2007) Complications of aortic atherosclerosis: Atheroemboli and thromboemboli. Current Treatment Options in Cardiovascular Medicine 9:2, 137-147
CrossRef106
Giampaolo Niccoli, Rocco Mongiardo, Gaetano A Lanza, Annalisa Ricco, Francesco Burzotta, Carlo Trani, Mario A Mazzari, Giovanna Liuzzo, Antonella Lombardo, Antonio G Rebuzzi, Paul Holvoet, Filippo Crea. (2007) The complex link between oxidised low-density lipoprotein and unstable angina. Journal of Cardiovascular Medicine 8:5, 387-391
CrossRef107
Bevra H. Hahn, Jennifer Grossman, Weiling Chen, Maureen McMahon. (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: Roles of inflammation and dyslipidemia. Journal of Autoimmunity 28:2-3, 69-75
CrossRef108
Jose S. Pulido, Joseph P. McConnell, Lisa M. Peterson, W. Edward Highsmith, Ryan J. Lennon, Sandra C. Bryant, Peter B. Berger, Virend Somers. (2007) Relationship Between Age-Related Macular Degeneration-Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease. Mayo Clinic Proceedings 82:3, 301-307
CrossRef109
J. S. Pulido, J. P. McConnell, L. M. Peterson, W. E. Highsmith, R. J. Lennon, S. C. Bryant, P. B. Berger, V. Somers. (2007) Relationship Between Age-Related Macular Degeneration-Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease. Mayo Clinic Proceedings 82:3, 301-307
CrossRef110
Simona Barlera, Claudia Specchia, Martin Farrall, Benedetta D Chiodini, Maria Grazia Franzosi, Stephan Rust, Fiona Green, Enrico B Nicolis, John Peden, Gerd Assmann, Rory Collins, Anders Hamsten, Gianni Tognoni, Hugh Watkins. (2007) Multiple QTL influence the serum Lp(a) concentration: a genome-wide linkage screen in the PROCARDIS study. European Journal of Human Genetics 15:2, 221-227
CrossRef111
Javier Sanz, Pedro R Moreno, Valentin Fuster. (2007) Update on advances in atherothrombosis. Nature Clinical Practice Cardiovascular Medicine 4:2, 78-89
CrossRef112
Fumiyuki Otsuka, Seigo Sugiyama, Sunao Kojima, Hidetomo Maruyoshi, Tohru Funahashi, Tomohiro Sakamoto, Michihiro Yoshimura, Kazuo Kimura, Satoshi Umemura, Hisao Ogawa. (2007) Hypoadiponectinemia is Associated With Impaired Glucose Tolerance and Coronary Artery Disease in Non-Diabetic Men. Circulation Journal 71:11, 1703-1709
CrossRef113
Angela Yee-Moon Wang, Stella Sin-Yee Ho, Eric Kin-Hung Liu, Iris Hiu-Shuen Chan, Simon Ho, John E. Sanderson, Christopher Wai-Kei Lam. (2007) Differential Associations of Traditional and Non-Traditional Risk Factors with Carotid Intima-Media Thickening and Plaque in Peritoneal Dialysis Patients. American Journal of Nephrology 27:5, 458-465
CrossRef114
Hajime Yamashita, Shoichi Ehara, Minoru Yoshiyama, Takahiko Naruko, Kazuo Haze, Nobuyuki Shirai, Yoshimi Sugama, Yoshihiro Ikura, Masahiko Ohsawa, Hiroyuki Itabe, Toru Kataoka, Yoshiki Kobayashi, Anton E. Becker, Junichi Yoshikawa, Makiko Ueda. (2007) Elevated Plasma Levels of Oxidized Low-Density Lipoprotein Relate to the Presence of Angiographically Detected Complex and Thrombotic Coronary Artery Lesion Morphology in Patients With Unstable Angina. Circulation Journal 71:5, 681-687
CrossRef115
Tamio Teramoto, Jun Sasaki, Hirotsugu Ueshima, Genshi Egusa, Makoto Kinoshita, Kazuaki Shimamoto, Hiroyuki Daida, Sadatoshi Biro, Kazuhiko Hirobe, Tohru Funahashi, Koutaro Yokote, Masayuki Yokode. (2007) Risk Factors of Atherosclerotic Diseases - Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for Japanese. Journal of Atherosclerosis and Thrombosis 14:6, 267-277
CrossRef116
M.T. Grebe, E. Schoene, C.A. Schaefer, R.H. Boedeker, B. Kemkes-Matthes, R. Voss, H.H. Tillmanns. (2007) Elevated Lipoprotein(a) does not promote early atherosclerotic changes of the carotid arteries in young, healthy adults. Atherosclerosis 190:1, 194-198
CrossRef117
Peter W.F. Wilson, Ori Ben-Yehuda, Judy McNamara, Joseph Massaro, Joseph Witztum, Peter D. Reaven. (2006) Autoantibodies to oxidized LDL and cardiovascular risk: The Framingham Offspring Study. Atherosclerosis 189:2, 364-368
CrossRef118
Peter Libby, Paul M. Ridker. (2006) Inflammation and Atherothrombosis. Journal of the American College of Cardiology 48:9, A33-A46
CrossRef119
Alexander E Fraley, Sotirios Tsimikas. (2006) Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Current Opinion in Lipidology 17:5, 502-509
CrossRef120
Gerhard Krönke, Norbert Leitinger. (2006) Oxidized phospholipids at the interface of innate and adaptive immunity. Future Lipidology 1:5, 623-630
CrossRef121
Mohamad Navab, GM Anantharamaiah, Srinivasa T Reddy, Alan M Fogelman. (2006) Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nature Clinical Practice Cardiovascular Medicine 3:10, 540-547
CrossRef122
Medha Rajappa, M.G. Sridhar, J. Balachander, K.R. Sethuraman. (2006) Lipoprotein (a) and comprehensive lipid tetrad index as a marker for coronary artery disease in NIDDM patients in South India. Clinica Chimica Acta 372:1-2, 70-75
CrossRef123
Fumiyuki Otsuka, Seigo Sugiyama, Sunao Kojima, Hidetomo Maruyoshi, Tohru Funahashi, Kunihiko Matsui, Tomohiro Sakamoto, Michihiro Yoshimura, Kazuo Kimura, Satoshi Umemura, Hisao Ogawa. (2006) Plasma Adiponectin Levels Are Associated With Coronary Lesion Complexity in Men With Coronary Artery Disease. Journal of the American College of Cardiology 48:6, 1155-1162
CrossRef124
Tianying Wu, Walter C. Willett, Nader Rifai, Iris Shai, JoAnn E. Manson, Eric B. Rimm. (2006) Is Plasma Oxidized Low-Density Lipoprotein, Measured With the Widely Used Antibody 4E6, an Independent Predictor of Coronary Heart Disease Among U.S. Men and Women?. Journal of the American College of Cardiology 48:5, 973-979
CrossRef125
Mohamad Navab, Gattadahalli M Anantharamaiah, Srinivasa T Reddy, Brian J Van Lenten, Benjamin J Ansell, Alan M Fogelman. (2006) Mechanisms of Disease: proatherogenic HDL—an evolving field. Nature Clinical Practice Endocrinology & Metabolism 2:9, 504-511
CrossRef126
Mohamad Navab, GM Anantharamaiah, Srinivasa T Reddy, Brian J Van Lenten, Geeta Datta, David Garber, Alan M Fogelman. (2006) Potential clinical utility of high-density lipoprotein-mimetic peptides. Current Opinion in Lipidology 17:4, 440-444
CrossRef127
Maureen McMahon, Jennifer Grossman, John FitzGerald, Erika Dahlin-Lee, Daniel J. Wallace, Bernard Y. Thong, Humeira Badsha, Kenneth Kalunian, Christina Charles, Mohamad Navab, Alan M. Fogelman, Bevra H. Hahn. (2006) Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis & Rheumatism 54:8, 2541-2549
CrossRef128
G MIRCESCU. (2006) Oxidative Stress: An Accomplice to Uremic Toxicity?. Journal of Renal Nutrition 16:3, 194-198
CrossRef129
GM Anantharamaiah, Mohamad Navab, Srinivasa T Reddy, David W Garber, Geeta Datta, Himanshu Gupta, C Roger White, Shaila P Handattu, Mayakonda N Palgunachari, Manjula Chaddha, Vinod K Mishra, Jere P Segrest, Alan M Fogelman. (2006) Synthetic peptides: managing lipid disorders. Current Opinion in Lipidology 17:3, 233-237
CrossRef130
Sotirios Tsimikas, Stefan Kiechl, Johann Willeit, Manuel Mayr, Elizabeth R. Miller, Florian Kronenberg, Qingbo Xu, Claes Bergmark, Siegfried Weger, Friedrich Oberhollenzer, Joseph L. Witztum. (2006) Oxidized Phospholipids Predict the Presence and Progression of Carotid and Femoral Atherosclerosis and Symptomatic Cardiovascular Disease. Journal of the American College of Cardiology 47:11, 2219-2228
CrossRef131
Jessica Rodenburg, Maud N. Vissers, Albert Wiegman, Elizabeth R. Miller, Paul M. Ridker, Joseph L. Witztum, John J.P. Kastelein, Sotirios Tsimikas. (2006) Oxidized Low-Density Lipoprotein in Children With Familial Hypercholesterolemia and Unaffected Siblings. Journal of the American College of Cardiology 47:9, 1803-1810
CrossRef132
Katsuyuki Nakajima, Takamitsu Nakano, Akira Tanaka. (2006) The oxidative modification hypothesis of atherosclerosis: The comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clinica Chimica Acta 367:1-2, 36-47
CrossRef133
Farouc A. Jaffer, Peter Libby, Ralph Weissleder. (2006) Molecular and Cellular Imaging of Atherosclerosis. Journal of the American College of Cardiology 47:7, 1328-1338
CrossRef134
Sotirios Tsimikas, James T. Willerson, Paul M. Ridker. (2006) C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients. Journal of the American College of Cardiology 47:8, C19-C31
CrossRef135
Salman Ashfaq, Jerome L. Abramson, Dean P. Jones, Steven D. Rhodes, William S. Weintraub, W. Craig Hooper, Viola Vaccarino, David G. Harrison, Arshed A. Quyyumi. (2006) The Relationship Between Plasma Levels of Oxidized and Reduced Thiols and Early Atherosclerosis in Healthy Adults. Journal of the American College of Cardiology 47:5, 1005-1011
CrossRef136
K. M. Kostner. (2006) Does lipoprotein(a) predict risk in type 2 diabetes?. European Journal of Clinical Investigation 36:2, 67-68
CrossRef137
Sotirios Tsimikas. (2006) Oxidized low-density lipoprotein biomarkers in atherosclerosis. Current Atherosclerosis Reports 8:1, 55-61
CrossRef138
Jia Liu, Mitchell H. Rosner. (2006) Endocrinology and Dialysis
Jean L. HolleySeries Editor: Lipid Abnormalities Associated with End-Stage Renal Disease. Seminars in Dialysis 19:1, 32-40
CrossRef139
Jan K. Damås, Pål Aukrust. (2006) Systemic markers of inflammation – are they useful predictive tools in coronary artery disease?. Scandinavian Cardiovascular Journal 40:5, 262-266
CrossRef140
Gary W. Williams. (2005) An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors. Current Pain and Headache Reports 9:6, 377-389
CrossRef141
Yury I Miller. (2005) Toll-like receptors and atherosclerosis: oxidized LDL as an endogenous Toll-like receptor ligand. Future Cardiology 1:6, 785-792
CrossRef142
Pål Aukrust, Arne Yndestad, Torgun Wæhre, Lars Gullestad, Bente Halvorsen, Jan Kristian Damås. (2005) Inflammation in coronary artery disease: potential role for immunomodulatory therapy. Expert Review of Cardiovascular Therapy 3:6, 1111-1124
CrossRef143
Berliner, Judith A., Watson, Andrew D., . (2005) A Role for Oxidized Phospholipids in Atherosclerosis. New England Journal of Medicine 353:1, 9-11
Full Text
